Infectious Diseases (all articles)
Europe is locking down a second time. But what is its long-term plan?
3 Nov, 2020 | 03:10h | UTCEurope is locking down a second time. But what is its long-term plan? – Science
WHO Q & A: COVID-19 Vaccines
2 Nov, 2020 | 02:38h | UTCCoronavirus disease (COVID-19): Vaccines – World Health Organization
Regeneron: Independent committee recommends holding trial enrollment in hospitalized patients with high oxygen requirements
2 Nov, 2020 | 02:31h | UTC
Commentary on Twitter
More potential evidence against antibody drugs late in course of #COVID19: Regeneron says independent cmte has recommended not enrolling pts on high oxygen into trial "based on a potential safety signal and an unfavorable risk/benefit profile at this time" https://t.co/moHtuhV9cP
— Meg Tirrell (@megtirrell) October 30, 2020
Strengthening the global response to climate change and infectious disease threats
2 Nov, 2020 | 02:29h | UTCStrengthening the global response to climate change and infectious disease threats – The BMJ
Commentary on Twitter
Climate change is emerging as an important driver of disease incidence. This #BMJInfographic introduces six strategies for intervening in the complex network of connections around climate change and infectious disease @will_s_t https://t.co/5SgFRoJTa9#virtualWISH2020 @WISHQatar pic.twitter.com/9iOzIJtXLj
— The BMJ (@bmj_latest) November 1, 2020
Cohort study: Risk of hospital admission with Covid-19 in healthcare workers and their households
2 Nov, 2020 | 02:35h | UTCCommentaries: High-risk COVID contact puts health workers, patients, families at risk – CIDRAP AND Health workers and their families account for 1 in 6 hospital COVID-19 cases – BMJ
Commentary on Twitter
NEW #BMJResearch Healthcare workers and their families account for 17% of hospital admissions for #COVID19 in the working age population (18-65 years): https://t.co/HsNkpBv2Xl
— The BMJ (@bmj_latest) November 1, 2020
CDC Report: Transmission of SARS-COV-2 infections in households
2 Nov, 2020 | 02:37h | UTCCommentaries: A new CDC study suggests roughly 50% of people living with someone who has COVID-19 get it — usually in less than 5 days – Business Insider AND Household spread of Covid-19 is common and quick, a new CDC study finds – CNN
Commentaries on Twitter
New CDC study finds that children pass along Covid to household members just as frequently as adults do. This underscores why it's crucial to contain the virus among all populations. https://t.co/sZHOh1wOG3
— Dr. Tom Frieden (@DrTomFrieden) October 31, 2020
(1/7) Important prospective study of household transmission by CDC, suggesting children and adults are similarly likely to transmit #SARSCoV2. The household secondary attack rate was at least 35%, and 18% of cases were asymptomatic.https://t.co/iEdx2VBPXz pic.twitter.com/mq4LxSoU0J
— Dr Zoë Hyde (@DrZoeHyde) October 31, 2020
Opinion – The evidence is clear: if countries act together, they can suppress Covid
2 Nov, 2020 | 02:27h | UTCThe evidence is clear: if countries act together, they can suppress Covid – The Guardian
The science of superspreading
2 Nov, 2020 | 02:30h | UTCThe science of superspreading – Science
Scientists warn Americans are expecting too much from a vaccine
2 Nov, 2020 | 02:25h | UTCScientists Warn Americans Are Expecting Too Much From a Vaccine – Kaiser Health News
Trends in COVID-19 risk-adjusted mortality rates
2 Nov, 2020 | 02:24h | UTCTrends in COVID-19 Risk-Adjusted Mortality Rates – Journal of Hospital Medicine
Commentary on Twitter
Trends in COVID-19 Risk-Adjusted Mortality Rates | Journal of Hospital Medicine: “Data from one health system suggest that mortality from COVID-19 is decreasing even after accounting for patient characteristics.” https://t.co/AtQ6lPnzhQ
— Dr. Ron Daniels BEM (@SepsisUK) October 25, 2020
Report: COVID-19 infection fatality ratio estimates from seroprevalence
30 Oct, 2020 | 01:16h | UTCFull report: COVID-19 Infection Fatality Ratio: Estimates from Seroprevalence
Commentary on Twitter
UPDATE #COVID19 Infection Fatality Ratio (IFR):
➡️1.15% IFR (high income countries)
➡️0.23% IFR (low income countries)
➡️0.1% IFR (under 40 year olds)
➡️5.6% IFR (over 80 year olds)
➡️Risk of COVID19 death doubles every eight years of age👇Report 34 https://t.co/171hx5LMvp pic.twitter.com/M1rmq673Rf
— MRC Centre for Global Infectious Disease Analysis (@MRC_Outbreak) October 29, 2020
CDC Report: 1 infected camper likely led to 115 coronavirus cases at an overnight camp
30 Oct, 2020 | 01:15h | UTCOriginal report: COVID-19 Outbreak at an Overnight Summer School Retreat ― Wisconsin, July–August 2020 – CDC Morbidity and Mortality Weekly Report
Commentary on Twitter
When 1 high school student who tested covid negative 1 week prior to a retreat led to 116 cases (76% of the students and staff)https://t.co/vjKImeE4vg @CDCgov
— Eric Topol (@EricTopol) October 29, 2020
Perspective: Will SARS-CoV-2 become endemic?
30 Oct, 2020 | 01:12h | UTCWill SARS-CoV-2 become endemic? – Science
It may be time to reset expectations on when we’ll get a Covid-19 vaccine
30 Oct, 2020 | 01:10h | UTCIt may be time to reset expectations on when we’ll get a Covid-19 vaccine – STAT
The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug
30 Oct, 2020 | 01:14h | UTCThe ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug – Science
Commentaries on Twitter
Remdesivir, despite failing in Solidarity trial, received FDA approval without input from outside advisory group. EU cut pricing deal with Gilead without knowing Solidarity data. @kakape and I explain in "The ‘very, very bad look’ of remdesivir" https://t.co/yTKq2A1WQT pic.twitter.com/NhBLum09VG
— Jon Cohen (@sciencecohen) October 28, 2020
Uncovering a scandal about Gilead and Remdesivir
Deep reporting by @sciencecohen and @kakape @ScienceMagazine
The company knew the #SOLIDARITY trial data well before it its preprint. And so did the FDA before giving a full approval, w/o external review https://t.co/4REMEwTvc5— Eric Topol (@EricTopol) October 28, 2020
Perspective: Why schools probably aren’t COVID hotspots
30 Oct, 2020 | 01:11h | UTCWhy schools probably aren’t COVID hotspots – Nature
Opinion: For now, it’s unethical to use human challenge studies for SARS-CoV-2 vaccine development
30 Oct, 2020 | 01:09h | UTC
A room, a bar and a classroom: how the coronavirus is spread through the air
30 Oct, 2020 | 01:08h | UTCA room, a bar and a classroom: how the coronavirus is spread through the air – El Pais
Commentary on Twitter (thread – click for more)
https://twitter.com/ASPphysician/status/1321798685991186434
Randomized phase 2 trial: SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19
29 Oct, 2020 | 09:16h | UTCAudio Interview: A New Monoclonal Antibody for Covid-19 – New England Journal of Medicine
Commentaries on Twitter
BLAZE-1🔥 – outpatient trial of LY-Cov555, mAb recently dropped from ACTIV-3 inpatient trial
Only 1 of the 3 mAb dosages (middle one 🤷♂️) ⬇️ VL by d11
mAb assoc with modest ⬇️ in healthcare visits (1.6% vs 6.3% for placebo)
😑 Far from a game changerhttps://t.co/zZMGlodaaF pic.twitter.com/ofs1UgN1ZA
— Ilan Schwartz is on🦋 (@GermHunterMD) October 28, 2020
Phase 2 Lilly #SARSCoV2 monoclonal antibody outpatient trial just published @NEJM
The lack of a dose response for viral load reduction +modest effects on symptoms do not make this look like a potent intervention https://t.co/oyRG8fUNHf pic.twitter.com/uobuCIznmD— Eric Topol (@EricTopol) October 28, 2020
Humoral immune response to SARS-CoV-2 in Iceland
29 Oct, 2020 | 09:18h | UTCHumoral Immune Response to SARS-CoV-2 in Iceland – New England Journal of Medicine
Editorial: The Power of Antibody-Based Surveillance – New England Journal of Medicine
Video: Coronavirus update with Anthony Fauci – October 28, 2020
29 Oct, 2020 | 09:11h | UTCCoronavirus Update With Anthony Fauci – October 28, 2020 – JAMA
Clinical practice: Mild or moderate Covid-19
29 Oct, 2020 | 09:12h | UTCMild or Moderate Covid-19 – New England Journal of Medicine
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
29 Oct, 2020 | 09:09h | UTC
Commentary on Twitter
NEW—What defines an efficacious #COVID19 vaccine? Experts @JennerInstitute@OxfordVacGroup @OxPrimaryCare & @OxfordBRC outline key challenges for assessing clinical efficacy of vaccines against SARS-CoV-2 @TheLancetInfDis https://t.co/QsLnLdUiYE pic.twitter.com/skpb0rfSdF
— The Lancet (@TheLancet) October 28, 2020
Clinical Decisions: Elective surgery during the Covid-19 pandemic
29 Oct, 2020 | 09:14h | UTCElective Surgery during the Covid-19 Pandemic – New England Journal of Medicine
Report: Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
29 Oct, 2020 | 09:08h | UTCRobust neutralizing antibodies to SARS-CoV-2 infection persist for months – Science
Commentary on Twitter
Just published @ScienceMagazine. >30,000 people w/mild to moderate #COVID19 have excellent IgG antibody titers for several months. No disappearing act. Important👍👍https://t.co/4kCZY8qcmo @MountSinaiNYC @FatimaAmanat @DrDavidReich @florian_krammer @IcahnMountSinai et al
, pic.twitter.com/B3LJ6JaBDa— Eric Topol (@EricTopol) October 28, 2020